Liver Diseases  >>  GSK 2336805  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GSK 2336805 / J&J
NCT01724086 / 2012-002555-42: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Checkmark Olysio + GSK-805 + TMC-055 combination in chronic genotype 1 hep C infected patients
Mar 2015 - Mar 2015: Olysio + GSK-805 + TMC-055 combination in chronic genotype 1 hep C infected patients
Completed
2a
90
Europe
TMC647055, JNJ-42039556-AMR-G-001, TMC435, Ritonavir, Ribavirin, Pegylated interferon alpha-2a (PegIFN), GSK2336805
Janssen R&D Ireland
Chronic Hepatitis C
09/14
12/14
NCT01439373: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Completed
2
16
US
GSK2336805, Pegylated interferon alfa-2a, Pegasys, Ribavirin, GSK2336805 Matching Placebo, Placebo
GlaxoSmithKline, PPD
Hepatitis C, Chronic
12/11
12/11
NCT01648140: Dose Ranging of GSK2336805 in Combination Therapy

Completed
2
286
US, Europe
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Pegasys, Ribavirin, Ribasphere, Telaprevir, Incivek (United States), Incivo (European Union)
GlaxoSmithKline, PPD
Hepatitis C, Chronic
07/14
07/14

Download Options